



PARTICIPANT STATISTICS

HEPATITIS MARKERS

SECOND QUADRIMESTER 2011

anti-HCV Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos
Abbott AxSYM			11	11			11					11	11		
Adaltis EIAGEN HCV			3	3			3					3	3		
Gen Biol SP-Nanabase			3	3			3					3	3		
J&J Vitros			8	8			8					8	8		
Ortho HCV Version 3.0 ELISA			16	16			15		1	1		15	16		
Siemens Advia			7	7			7					7	7		
Abbott Architect			5	5			5					5	5		
Roche Cobas/Elecsys			5	2			3		5			5	5		
Total Population	0	0	60	57	0	3	59	0	1	1	0	59	60	0	0
Flagging	*****	*****			*****	*****			*****	*****	*****	*****			*****

anti-HBc IgG + IgM Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos
Abbott AxSYM Core	9			9						9	9				
Bio-Rad MONOLISA EIA	4			3	1					4	4				
DiaSorin ETI-AB-COREK/Plus	4			4						4	2		2		
J&J Vitros	6			6						6	6				
Siemens Advia	5			5						5	5				
Siemens Immulite 2000	7			7						7	6		1	1	
Total Population	38	0	0	37	1	0	0	0	38	35	0	3	1	0	37
Flagging	*****	*****		*****	*****	*****	*****	*****		*****	*****	*****	*****	*****	*****

anti-HBc IgM Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos
Abbott Core-M	3			3			3			3			3		
DiaSorin ETI-CORE-IGMK Plus	4			4			1			3			4		
J&J Vitros	4			4						4			4		
Siemens Advia	3			3						3			3		3
Siemens Immulite	5			5			3	1	1	5			5		
Bio-Rad MONOLISA EIA	3			3						3			3		
Total Population	23	0	0	23	0	0	11	1	11	23	0	0	19	0	4
Flagging	*****	*****		*****	*****					*****	*****	*****	*****	*****	*****

Due to lack of participant consensus, Specimen 3 was not evaluated this event.

anti-HBs Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos
Abbott Architect	4					4	4			4					4
Abbott AxSYM AUSAB	6					6	6			6					6
Bio-Rad MONOLISA EIA	3					3	3			3					3
DiaSorin ETI-AB-AUK Plus	9			1		8	8		1	9			1		8
J&J Vitros	6					6	6			6					6
Roche Elecsys	12					12	12			11			1		12
Siemens Advia	5					5	5			4			1		5
Siemens Immulite	9					9	9			9					9
Total Population	57	0	0	1	0	56	56	0	1	55	0	2	1	0	56
Flagging	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****

anti-HBeAg Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos
DiaSorin ETI-EBK Plus	4			4			4			4			4		
General Biologicals Co	1			1						1			1		
Total Population	5	0	0	5	0	0	0	0	0	5	0	0	5	0	0
Flagging	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****

HBsAg Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Ind	Pos	Neg	Ind	Pos	Ind	Reac	Pos	Neg	Ind	Pos	Neg	Ind	Pos
Abbott Architect	6			6					1	5	6			6	
Abbott ImX/AxSYM	6		2	8					1	7	8			7	1
Bio-Rad EIA-Proc A	9			9						9	9			9	
Bio-Rad MONOLISA AgHBs +	2			2						2	2			2	
Bio-Rad MONOLISA Ultra	5			5						5	5			4	1
DiaSorin ETI-MAK-2 Plus	5			5					1	4	5			5	
DiaSorin ETI-MAK-2 Proc A	3			3						3	3			3	
J&J Vitros ECI	9			9						9	9			9	
Roche Elecsys	14			14					3	11	13		1	13	1
Siemens Advia	8			8						8	8			8	
Siemens Immulite	21			21			1	1	19	21				21	
Total Population	91	0	2	93	0	0	1	7	85	92	0	1	90	1	2
Flagging	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****

Correct responses are defined as those reflecting agreement among 80% or more of all participants or referees. Unacceptable responses are indicated by "*****" on the Flagging line of each specimen.